Browse studies

Find your next paid study

25,415 recruiting studies available now

Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease

Background: Normal aging, as well as dementias such as Alzheimer s disease, can cause changes in the brain that affect memory, attention, and thinking. Resear…

Alzheimer's Disease

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Institute on Aging (NIA)NCT07721467

Phase 3

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

This phase III trial compares the effect of bevacizumab in combination with carboplatin, paclitaxel and pembrolizumab to the usual treatments of carboplatin an…

Advanced Endometrial CarcinomaRecurrent Endometrial Carcinoma

Estimated

~$50 – $1,350

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07198074

Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Misetionamide (GP-2250) as Monotherapy or in Combination With Gemcitabine in Subjects With Advanced Solid Tumors

This is a phase 1 dose escalation trial of monotherapy misetionamide (also known as GP-2250) currently enrolling patients with platinum-resistant ovarian cance…

Ovarian Cancer

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Persevere Therapeutics Inc.NCT03854110

Observational

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who ac…

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $675

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT05621291

Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults

Background: Diabetes and obesity are chronic diseases. They can affect blood flow and how the body processes nutrients, and complications over time can lead t…

ObesityDiabetesMetabolic Disorders

Estimated

~$10 – $675

Actual pay is set by the research site.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT07388537

Observational

A Pilot Feasibility Study of an Intervention to Reduce Chronic Pain Following Cesarean Delivery

This pilot study will evaluate the feasibility and acceptability of delivering Empowered Relief (ER), a single-session pain relief skills class, to postpartum …

Chronic PainCesarean Section ComplicationsPostpartum

Estimated

~$10 – $750

Actual pay is set by the research site.

Stanford UniversityNCT07799883

Phase 2

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) v…

Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor

Estimated

~$75 – $2,800

Actual pay is set by the research site.

CatalYm GmbHNCT07098988

Phase 3

A Phase 3 Open-label Extension Study to Investigate the Long-term Safety and Efficacy of Orally Administered NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome

This Phase 3, open-label extension, multicenter study will evaluate long-term safety, tolerability and efficacy of NNZ-2591 in pediatric participants with Phel…

Phelan-McDermid Syndrome

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Neuren Pharmaceuticals LimitedNCT07593391

Phase 2

A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination With Palbociclib, a CDK4/6 Inhibitor, in Patients With HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial

This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positi…

Malignant Female Reproductive System NeoplasmMalignant Solid NeoplasmRecurrent Malignant Female Reproductive System Neoplasm+1 more

Estimated

~$75 – $1,800

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT06126276

Phase 1

A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of T Cell Engaging Bi/Tri-specific Antibodies in Subjects With MM

Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bone…

Multiple Myeloma

Estimated

~$150 – $4,500

Actual pay is set by the research site.

AbbVieNCT06892522

Phase 4

Sequential Multiple Assignment Randomized Trial to Treat Urinary Symptoms in Parkinson Disease

The purpose of this study is to learn about different treatments for overactive bladder symptoms in Parkinson's Disease. The investigators want to find out if …

Overactive BladderParkinson Disease

Estimated

~$25 – $900

Actual pay is set by the research site.

VA Office of Research and DevelopmentNCT07187466

Phase 1

A Phase 1b/2, Open-label, Multi-center Study to Evaluate the Anti-cancer Activity, Safety and Tolerability of GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig [T-CELL-Redirecting Agent Targeting Human Kallikrein 2 (KLK2)] in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Who Progressed on Previous Novel Hormonal Therapy (NHT) (JET-201)

The purpose of this clinical trial is to evaluate the safety, tolerability, and preliminary anti-cancer activity of GI-102 in combination with pasritamig in ad…

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Estimated

~$150 – $4,200

Actual pay is set by the research site.

GI Innovation, Inc.NCT07871435